Literature DB >> 28232017

MicroRNAs in the Pathobiology and Therapy of Atherosclerosis.

Benoit Laffont1, Katey J Rayner2.   

Abstract

MicroRNAs are short noncoding RNAs, expressed in humans and involved in sequence-specific post-transcriptional regulation of gene expression. They have emerged as key players in a wide array of biological processes, and changes in their expression and/or function have been associated with plethora of human diseases. Atherosclerosis and its related clinical complications, such as myocardial infarction or stroke, represent the leading cause of death in the Western world. Accumulating experimental evidence has revealed a key role for microRNAs in regulating cellular and molecular processes related to atherosclerosis development, ranging from risk factors, to plaque initiation and progression, up to atherosclerotic plaque rupture. In this review, we focus on how microRNAs can influence atherosclerosis biology, as well as the potential clinical applications of microRNAs, which are being developed as targets as well as therapeutic agents for a growing industry hoping to harness the power of RNA-guided gene regulation to fight disease and infection.
Copyright © 2017 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28232017      PMCID: PMC5421617          DOI: 10.1016/j.cjca.2017.01.001

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  125 in total

Review 1.  The widespread regulation of microRNA biogenesis, function and decay.

Authors:  Jacek Krol; Inga Loedige; Witold Filipowicz
Journal:  Nat Rev Genet       Date:  2010-07-27       Impact factor: 53.242

2.  MicroRNA-155 regulates lipid uptake, adhesion/chemokine marker secretion and SCG2 expression in oxLDL-stimulated dendritic cells/macrophages.

Authors:  Ting Chen; Hui Yan; Zhoubin Li; Tu Jing; Weiguo Zhu; Junhua Ge; Xiaoye Zheng; Xiaoping Pan; Hui Yan; Jianhua Zhu
Journal:  Int J Cardiol       Date:  2011-01-26       Impact factor: 4.164

3.  Regulation of Csf1r and Bcl6 in macrophages mediates the stage-specific effects of microRNA-155 on atherosclerosis.

Authors:  Yuanyuan Wei; Mengyu Zhu; Judit Corbalán-Campos; Kathrin Heyll; Christian Weber; Andreas Schober
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-02-19       Impact factor: 8.311

4.  Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis.

Authors:  Katey J Rayner; Frederick J Sheedy; Christine C Esau; Farah N Hussain; Ryan E Temel; Saj Parathath; Janine M van Gils; Alistair J Rayner; Aaron N Chang; Yajaira Suarez; Carlos Fernandez-Hernando; Edward A Fisher; Kathryn J Moore
Journal:  J Clin Invest       Date:  2011-06-06       Impact factor: 14.808

5.  The microRNA miR-29 controls innate and adaptive immune responses to intracellular bacterial infection by targeting interferon-γ.

Authors:  Feng Ma; Sheng Xu; Xingguang Liu; Qian Zhang; Xiongfei Xu; Mofang Liu; Minmin Hua; Nan Li; Hangping Yao; Xuetao Cao
Journal:  Nat Immunol       Date:  2011-07-24       Impact factor: 25.606

6.  Let-7g improves multiple endothelial functions through targeting transforming growth factor-beta and SIRT-1 signaling.

Authors:  Yi-Chu Liao; Yung-Song Wang; Yuh-Cherng Guo; Wen-Lien Lin; Ming-Hung Chang; Suh-Hang Hank Juo
Journal:  J Am Coll Cardiol       Date:  2013-11-27       Impact factor: 24.094

7.  A novel regulator of macrophage activation: miR-223 in obesity-associated adipose tissue inflammation.

Authors:  Guoqing Zhuang; Cong Meng; Xin Guo; Patali S Cheruku; Lei Shi; Hang Xu; Honggui Li; Gang Wang; Ashley R Evans; Stephen Safe; Chaodong Wu; Beiyan Zhou
Journal:  Circulation       Date:  2012-05-11       Impact factor: 29.690

8.  MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins.

Authors:  Kasey C Vickers; Brian T Palmisano; Bassem M Shoucri; Robert D Shamburek; Alan T Remaley
Journal:  Nat Cell Biol       Date:  2011-03-20       Impact factor: 28.824

9.  Hematopoietic miR155 deficiency enhances atherosclerosis and decreases plaque stability in hyperlipidemic mice.

Authors:  Marjo M P C Donners; Ine M J Wolfs; Lauran J Stöger; Emiel P C van der Vorst; Chantal C H Pöttgens; Stephane Heymans; Blanche Schroen; Marion J J Gijbels; Menno P J de Winther
Journal:  PLoS One       Date:  2012-04-25       Impact factor: 3.240

10.  Targeting Axl with an high-affinity inhibitory aptamer.

Authors:  Laura Cerchia; Carla L Esposito; Simona Camorani; Anna Rienzo; Loredana Stasio; Luigi Insabato; Andrea Affuso; Vittorio de Franciscis
Journal:  Mol Ther       Date:  2012-08-21       Impact factor: 11.454

View more
  49 in total

1.  Targeting epigenetics and non-coding RNAs in atherosclerosis: from mechanisms to therapeutics.

Authors:  Suowen Xu; Danielle Kamato; Peter J Little; Shinichi Nakagawa; Jaroslav Pelisek; Zheng Gen Jin
Journal:  Pharmacol Ther       Date:  2018-11-13       Impact factor: 12.310

Review 2.  Pathogenic role of exosomes and microRNAs in HPV-mediated inflammation and cervical cancer: A review.

Authors:  Javid Sadri Nahand; Mohsen Moghoofei; Arash Salmaninejad; Zahra Bahmanpour; Mohammad Karimzadeh; Mitra Nasiri; Hamid Reza Mirzaei; Mohammad Hossein Pourhanifeh; Farah Bokharaei-Salim; Hamed Mirzaei; Michael R Hamblin
Journal:  Int J Cancer       Date:  2019-10-31       Impact factor: 7.396

3.  Dual inhibition of endothelial miR-92a-3p and miR-489-3p reduces renal injury-associated atherosclerosis.

Authors:  Carrie B Wiese; Jianyong Zhong; Zhi-Qi Xu; Youmin Zhang; Marisol A Ramirez Solano; Wanying Zhu; MacRae F Linton; Quanhu Sheng; Valentina Kon; Kasey C Vickers
Journal:  Atherosclerosis       Date:  2019-01-30       Impact factor: 5.162

4.  Reduced atherosclerosis lesion size, inflammatory response in miR-150 knockout mice via macrophage effects.

Authors:  Fu-Han Gong; Wen-Lin Cheng; Haiping Wang; Maomao Gao; Juan-Juan Qin; Yan Zhang; Xia Li; Xueyong Zhu; Hao Xia; Zhi-Gang She
Journal:  J Lipid Res       Date:  2018-02-20       Impact factor: 5.922

5.  Downregulation of miR-34a promotes endothelial cell growth and suppresses apoptosis in atherosclerosis by regulating Bcl-2.

Authors:  Gang Su; Guangli Sun; Hai Liu; Liliang Shu; Zhenxing Liang
Journal:  Heart Vessels       Date:  2018-04-27       Impact factor: 2.037

Review 6.  MicroRNA-based therapeutics in central nervous system injuries.

Authors:  Ping Sun; Da Zhi Liu; Glen C Jickling; Frank R Sharp; Ke-Jie Yin
Journal:  J Cereb Blood Flow Metab       Date:  2018-04-30       Impact factor: 6.200

7.  MicroRNA-374 is a potential diagnostic biomarker for atherosclerosis and regulates the proliferation and migration of vascular smooth muscle cells.

Authors:  Weihong Wang; Fenghua Ma; Hongyan Zhang
Journal:  Cardiovasc Diagn Ther       Date:  2020-08

8.  MiR-29b mimics promotes cell apoptosis of smooth muscle cells via targeting on MMP-2.

Authors:  Lingguang Shen; Yanhui Song; Yuqin Fu; Peipei Li
Journal:  Cytotechnology       Date:  2017-10-07       Impact factor: 2.058

9.  Significances of viable synergistic autophagy-associated cathepsin B and cathepsin D (CTSB/CTSD) as potential biomarkers for sudden cardiac death.

Authors:  Jialin Dai; Qiong Zhang; Changwu Wan; Jiangjin Liu; Qiaojun Zhang; Yanni Yu; Jie Wang
Journal:  BMC Cardiovasc Disord       Date:  2021-05-08       Impact factor: 2.298

10.  Sufentanil preconditioning protects against myocardial ischemia/reperfusion injury via miR-125a/DRAM2 axis.

Authors:  Qiaoling Wu; You Shang; Yanli Bai; Yuanyuan Wu; Hao Wang; Tu Shen
Journal:  Cell Cycle       Date:  2021-01-21       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.